Your browser doesn't support javascript.
Chimeric Peptides from Californiconus californicus and Heterodontus francisci with Antigen-Binding Capacity: A Conotoxin Scaffold to Create Non-Natural Antibodies (NoNaBodies).
Dueñas, Salvador; Escalante, Teresa; Gasperin-Bulbarela, Jahaziel; Bernáldez-Sarabia, Johanna; Cervantes-Luévano, Karla; Jiménez, Samanta; Sánchez-Campos, Noemí; Cabanillas-Bernal, Olivia; Valdovinos-Navarro, Blanca J; Álvarez-Lee, Angélica; De León-Nava, Marco A; Licea-Navarro, Alexei F.
  • Dueñas S; Departamento de Innovación Biomédica, CICESE, Carretera Ensenada-Tijuana 3918, Ensenada C.P. 22860, Mexico.
  • Escalante T; Instituto Clodomiro Picado, Facultad de Microbiología, Universidad de Costa Rica, San José 11501, Costa Rica.
  • Gasperin-Bulbarela J; Departamento de Innovación Biomédica, CICESE, Carretera Ensenada-Tijuana 3918, Ensenada C.P. 22860, Mexico.
  • Bernáldez-Sarabia J; Departamento de Innovación Biomédica, CICESE, Carretera Ensenada-Tijuana 3918, Ensenada C.P. 22860, Mexico.
  • Cervantes-Luévano K; Departamento de Innovación Biomédica, CICESE, Carretera Ensenada-Tijuana 3918, Ensenada C.P. 22860, Mexico.
  • Jiménez S; Departamento de Innovación Biomédica, CICESE, Carretera Ensenada-Tijuana 3918, Ensenada C.P. 22860, Mexico.
  • Sánchez-Campos N; Departamento de Innovación Biomédica, CICESE, Carretera Ensenada-Tijuana 3918, Ensenada C.P. 22860, Mexico.
  • Cabanillas-Bernal O; Departamento de Innovación Biomédica, CICESE, Carretera Ensenada-Tijuana 3918, Ensenada C.P. 22860, Mexico.
  • Valdovinos-Navarro BJ; Departamento de Innovación Biomédica, CICESE, Carretera Ensenada-Tijuana 3918, Ensenada C.P. 22860, Mexico.
  • Álvarez-Lee A; Departamento de Innovación Biomédica, CICESE, Carretera Ensenada-Tijuana 3918, Ensenada C.P. 22860, Mexico.
  • De León-Nava MA; Departamento de Innovación Biomédica, CICESE, Carretera Ensenada-Tijuana 3918, Ensenada C.P. 22860, Mexico.
  • Licea-Navarro AF; Departamento de Innovación Biomédica, CICESE, Carretera Ensenada-Tijuana 3918, Ensenada C.P. 22860, Mexico.
Toxins (Basel) ; 15(4)2023 04 04.
Article in English | MEDLINE | ID: covidwho-2294485
ABSTRACT
Research into various proteins capable of blocking metabolic pathways has improved the detection and treatment of multiple pathologies associated with the malfunction and overexpression of different metabolites. However, antigen-binding proteins have limitations. To overcome the disadvantages of the available antigen-binding proteins, the present investigation aims to provide chimeric antigen-binding peptides by binding a complementarity-determining region 3 (CDR3) of variable domains of new antigen receptors (VNARs) with a conotoxin. Six non-natural antibodies (NoNaBodies) were obtained from the complexes of conotoxin cal14.1a with six CDR3s from the VNARs of Heterodontus francisci and two NoNaBodies from the VNARs of other shark species. The peptides cal_P98Y vs. vascular endothelial growth factor 165 (VEGF165), cal_T10 vs. transforming growth factor beta (TGF-ß), and cal_CV043 vs. carcinoembryonic antigen (CEA) showed in-silico and in vitro recognition capacity. Likewise, cal_P98Y and cal_CV043 demonstrated the capacity to neutralize the antigens for which they were designed.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Sharks / Conotoxins / Gastropoda Limits: Animals Language: English Year: 2023 Document Type: Article Affiliation country: Toxins15040269

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Sharks / Conotoxins / Gastropoda Limits: Animals Language: English Year: 2023 Document Type: Article Affiliation country: Toxins15040269